
## Polona Å1/2igon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/783807/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Olive Leaf Extract Attenuates Inflammatory Activation and DNA Damage in Human Arterial Endothelial Cells. Frontiers in Cardiovascular Medicine, 2019, 6, 56.	2.4	83
2	Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus, 2017, 26, 266-276.	1.6	53
3	Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements. Clinical Rheumatology, 2019, 38, 371-378.	2.2	40
4	Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes. Journal of Immunology Research, 2015, 2015, 1-8.	2.2	39
5	Detection of Antiphosphatidylserine/Prothrombin Antibodies and Their Potential Diagnostic Value. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	34
6	Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus, 2012, 21, 175-183.	1.6	32
7	Utility of serological biomarkers for giant cell arteritis in a large cohort of treatment-naÃ <sup>-</sup> ve patients. Clinical Rheumatology, 2019, 38, 317-329.	2.2	32
8	The Importance of Antibacterial Surfaces in Biomedical Applications. Advances in Biomembranes and Lipid Self-Assembly, 2018, 28, 115-165.	0.6	28
9	Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. Rheumatology, 2013, 52, 1775-1784.	1.9	25
10	Serum amyloid A in autoimmune thrombosis. Autoimmunity Reviews, 2006, 6, 21-27.	5.8	24
11	Modified phosphatidylserine-dependent antithrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1011-8.	2.3	24
12	Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study. RMD Open, 2020, 6, e001340.	3.8	23
13	Characterization of Plasma-Derived Small Extracellular Vesicles Indicates Ongoing Endothelial and Platelet Activation in Patients with Thrombotic Antiphospholipid Syndrome. Cells, 2020, 9, 1211.	4.1	20
14	A concise review of significantly modified serological biomarkers in giant cell arteritis, as detected by different methods. Autoimmunity Reviews, 2018, 17, 188-194.	5.8	19
15	Insight into inflammatory cell and cytokine profiles in adult IgA vasculitis. Clinical Rheumatology, 2019, 38, 331-338.	2.2	19
16	Stroke and antiphospholipid syndrome—antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event. Clinical Rheumatology, 2019, 38, 379-384.	2.2	19
17	Comparison and evaluation of different methodologies and tests for detection of anti-dsDNA antibodies on 889 Slovenian patients' and blood donors' sera. Croatian Medical Journal, 2011, 52, 694-702.	0.7	17
18	COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases. Frontiers in Immunology, 2020, 11, 611318.	4.8	17

Polona Žigon

#	Article	IF	CITATIONS
19	Binding of human coronary artery endothelial cells to plasmaâ€ŧreated titanium dioxide nanotubes of different diameters. Journal of Biomedical Materials Research - Part A, 2016, 104, 1113-1120.	4.0	16
20	Antibodies against acute phase proteins and their functions in the pathogenesis of disease: A collective profile of 25 different antibodies. Autoimmunity Reviews, 2011, 10, 779-789.	5.8	15
21	Antibodies to phosphatidylserine/prothrombin complex as an additional diagnostic marker of APS?. Lupus, 2012, 21, 790-792.	1.6	13
22	Extracellular Vesicles and Antiphospholipid Syndrome: State-of-the-Art and Future Challenges. International Journal of Molecular Sciences, 2021, 22, 4689.	4.1	9
23	Autoantibodies against dsDNA measured with nonradioactive Farr assay—an alternative for routine laboratories. Clinical Rheumatology, 2019, 38, 353-359.	2.2	8
24	Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels. Immunologic Research, 2018, 66, 726-736.	2.9	7
25	From Active to Non-active Giant Cell Arteritis: Longitudinal Monitoring of Patients on Glucocorticoid Therapy in Combination With Leflunomide. Frontiers in Medicine, 2021, 8, 827095.	2.6	7
26	Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA. Clinical Rheumatology, 2019, 38, 361-370.	2.2	6
27	Metabolic fingerprints of human primary endothelial and fibroblast cells. Metabolomics, 2016, 12, 92.	3.0	4
28	Antiphospholipid antibodies in adult IgA vasculitis: observational study. Clinical Rheumatology, 2019, 38, 347-351.	2.2	4
29	Modified phosphatidylserine-dependent antiprothrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies. Clinical Chemistry and Laboratory Medicine, 2011, 49, .	2.3	3
30	Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated by Serum Amyloid A. Mediators of Inflammation, 2018, 2018, 1-11.	3.0	3
31	Gene and miRNA expression in giant cell arteritis—a concise systematic review of significantly modified studies. Clinical Rheumatology, 2019, 38, 307-316.	2.2	3
32	Neutralizing effects of anti-infliximab antibodies on synergistically-stimulated human coronary artery endothelial cells. Atherosclerosis, 2019, 291, 1-8.	0.8	3
33	The Predictive Value of the aCL and Anti-β2GPI at the Time of Acute Deep Vein Thrombosis—A Two-Year Prospective Study. Biomedicines, 2021, 9, 901.	3.2	2
34	Do antiphospholipid antibodies enhance thromboembolic risk in patients with cancer?. Polish Archives of Internal Medicine, 2020, 130, 1026-1028.	0.4	2
35	OP0223â€Significance of IGG Phosphatidylserine-Dependent Antiprothrombin Antibody Testing for the Diagnosis of Antiphospholipid Syndrome: Results from the Initial and Validation International Multi-Centre Studies. Annals of the Rheumatic Diseases, 2015, 74, 155.2-156.	0.9	1
36	Laboratory Methodology Important in the Diagnosis and Prognosis of Antiphospholipid Syndrome. , 2015, , .		1

3

Polona Žigon

#	Article	IF	CITATIONS
37	AB0552â€Antiphospholipid antibodies in giant cell arteritis. , 2017, , .		1
38	Protective Effects Of Olive Leaf Extract On Inflammatory Activation Of Endothelial Cells. Atherosclerosis, 2019, 287, e95.	0.8	1
39	Antibodies Against Acute Phase Proteins. , 2014, , 67-73.		Ο
40	SAT0202â€International Multi-Centre Study to Evaluate the Clinical Significance of Phosphatidylserine-Dependent Antiprothrombin Antibodies for the Diagnosis of Antiphospholipid Syndrome. Annals of the Rheumatic Diseases, 2014, 73, 662.3-663.	0.9	0
41	SAT0418â€IGA Anti-Phosphatidylserin/Prothrombin Antibodies Present a Thrombotic Risk in Patients with Systemic Autoimmune Diseases: Table 1. Annals of the Rheumatic Diseases, 2015, 74, 810.3-811.	0.9	Ο
42	SAT0414â€Antiphospholipid Antibodies in Patients with Cerebrovascular Events. Annals of the Rheumatic Diseases, 2015, 74, 809.1-809.	0.9	0
43	08.15â€Stability of infliximab under different storage conditions used as a standard for in-house infliximab elisa. , 2017, , .		0
44	THU0324â€Neutrophils in giant cell arteritis: monitoring disease progression during therapy tapering. , 2017, , .		0
45	THU0054â€Utility of serological parameters in giant cell arteritis for predicting disease complications. , 2017, , .		0
46	FRI0516â€Insight into inflammatory cell and cytokine profiles in adult iga vasculitis. , 2018, , .		0
47	THU0306â€NEUTROPHIL ADHESION MOLECULES AND INFLAMMATORY CYTOKINES AS BIOMARKERS FOR MONITORING DISEASE PROGRESSION IN GIANT CELL ARTERITIS. , 2019, , .		0
48	Extracellular Vesicles: Intercellular Communication Mediators in Antiphospholipid Syndrome. , 0, , .		0
49	PROTITELESA PROTI PROTROMBINU. ZdravniÅjki Vestnik, 2015, 84, .	0.1	0
50	SAT0192â€Competitive elisa and bridging elisa with acid dissociation detect anti-drug antibodies in a greater proportion of patients treated with tnf-Î'lpha inhibitors than classical bridging elisa. , 2018, , .		0
51	Zgodnji gigantoceliÄni arteritis. ZdravniÅįki Vestnik, 2018, 87, .	0.1	0
52	Introductory Chapter: Antiphospholipid Antibodies - A Laboratory Criterion for the Antiphospholipid Syndrome, but Also Bystanders in Infections, Cancer, and Other Conditions. , 0, , .		0